Ondine Biopharma Receives CE Mark Approval for PERIOWAVE
"CE Mark approval permits us to expand our market reach beyond Canada, where Periowave(TM) is currently being sold," said Carolyn Cross, President and CEO of Ondine Biopharma. "The CE Mark also indicates that we have met the essential health, safety and environmental protection requirements detailed in the European Directives covering medical devices." Periowave(TM) is a Photodynamic Disinfection system that utilizes low-intensity lasers and wavelength-specific, light-activated compounds to specifically target and destroy microbial pathogens and reduce the symptoms of disease. The compounds are generally topically applied and one or more lasers are used to activate the compounds and complete the disinfection. The Photodynamic Disinfection technologies were developed by Professor Michael Wilson and colleagues at the Eastman Dental Institute, University College London, and licensed to Ondine by UCL Biomedica PLC, University College London.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.